185 related articles for article (PubMed ID: 31278695)
1. Determining MRI Inflammation Targets When Considering a Rheumatoid Arthritis Treat-to-Target Strategy: Results of a Randomized, Placebo-Controlled Trial.
Ahmad HA; Baker JF; Østergaard M; Ye J; Emery P; Conaghan PG
Adv Ther; 2019 Sep; 36(9):2384-2393. PubMed ID: 31278695
[TBL] [Abstract][Full Text] [Related]
2. Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials.
Keystone EC; Ahmad HA; Yazici Y; Bergman MJ
Rheumatology (Oxford); 2020 Aug; 59(8):2090-2098. PubMed ID: 31819995
[TBL] [Abstract][Full Text] [Related]
3. Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor Prognosis.
Ahmad HA; Baker JF; Østergaard M; Emery P; Durez P; Ye J; Banerjee S; Conaghan PG
Arthritis Care Res (Hoboken); 2020 Jul; 72(7):959-964. PubMed ID: 31549793
[TBL] [Abstract][Full Text] [Related]
4. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial.
Conaghan PG; Durez P; Alten RE; Burmester GR; Tak PP; Klareskog L; Catrina AI; DiCarlo J; Gaillez C; Le Bars M; Zhou X; Peterfy C
Ann Rheum Dis; 2013 Aug; 72(8):1287-94. PubMed ID: 22915624
[TBL] [Abstract][Full Text] [Related]
5. Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis.
Peterfy C; Burmester GR; Bykerk VP; Combe BG; DiCarlo JC; Furst DE; Huizinga TW; Wong DA; Conaghan PG; Emery P
Ann Rheum Dis; 2016 Aug; 75(8):1501-5. PubMed ID: 26865601
[TBL] [Abstract][Full Text] [Related]
6. A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial.
Axelsen MB; Eshed I; Hørslev-Petersen K; Stengaard-Pedersen K; Hetland ML; Møller J; Junker P; Pødenphant J; Schlemmer A; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Krogh NS; Johansen JS; Østergaard M;
Ann Rheum Dis; 2015 May; 74(5):867-75. PubMed ID: 24412895
[TBL] [Abstract][Full Text] [Related]
7. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA).
Hetland ML; Ejbjerg B; Hørslev-Petersen K; Jacobsen S; Vestergaard A; Jurik AG; Stengaard-Pedersen K; Junker P; Lottenburger T; Hansen I; Andersen LS; Tarp U; Skjødt H; Pedersen JK; Majgaard O; Svendsen AJ; Ellingsen T; Lindegaard H; Christensen AF; Vallø J; Torfing T; Narvestad E; Thomsen HS; Ostergaard M;
Ann Rheum Dis; 2009 Mar; 68(3):384-90. PubMed ID: 18388160
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance imaging of the hand and wrist in a randomized, double-blind, multicenter, placebo-controlled trial of infliximab for rheumatoid arthritis: Comparison of dynamic contrast enhanced assessments with semi-quantitative scoring.
Beals C; Baumgartner R; Peterfy C; Balanescu A; Mirea G; Harabagiu A; Popa S; Cheng A; Feng D; Ashton E; DiCarlo J; Vallee MH; Dardzinski BJ
PLoS One; 2017; 12(12):e0187397. PubMed ID: 29236711
[TBL] [Abstract][Full Text] [Related]
9. Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept.
Ahmad HA; Baker JF; Conaghan PG; Emery P; Huizinga TWJ; Elbez Y; Banerjee S; Østergaard M
Arthritis Res Ther; 2022 Feb; 24(1):47. PubMed ID: 35172859
[TBL] [Abstract][Full Text] [Related]
10. Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis: The IMAGINE-RA Randomized Clinical Trial.
Møller-Bisgaard S; Hørslev-Petersen K; Ejbjerg B; Hetland ML; Ørnbjerg LM; Glinatsi D; Møller J; Boesen M; Christensen R; Stengaard-Pedersen K; Madsen OR; Jensen B; Villadsen JA; Hauge EM; Bennett P; Hendricks O; Asmussen K; Kowalski M; Lindegaard H; Nielsen SM; Bliddal H; Krogh NS; Ellingsen T; Nielsen AH; Balding L; Jurik AG; Thomsen HS; Østergaard M
JAMA; 2019 Feb; 321(5):461-472. PubMed ID: 30721294
[TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance imaging assessed inflammation in the wrist is associated with patient-reported physical impairment, global assessment of disease activity and pain in early rheumatoid arthritis: longitudinal results from two randomised controlled trials.
Glinatsi D; Baker JF; Hetland ML; Hørslev-Petersen K; Ejbjerg BJ; Stengaard-Pedersen K; Junker P; Ellingsen T; Lindegaard HM; Hansen I; Lottenburger T; Møller JM; Ørnbjerg L; Vestergaard A; Jurik AG; Thomsen HS; Torfing T; Møller-Bisgaard S; Axelsen MB; Østergaard M
Ann Rheum Dis; 2017 Oct; 76(10):1707-1715. PubMed ID: 28611080
[TBL] [Abstract][Full Text] [Related]
12. MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study.
Peterfy C; Emery P; Tak PP; Østergaard M; DiCarlo J; Otsa K; Navarro Sarabia F; Pavelka K; Bagnard MA; Gylvin LH; Bernasconi C; Gabriele A
Ann Rheum Dis; 2016 Jan; 75(1):170-7. PubMed ID: 25355728
[TBL] [Abstract][Full Text] [Related]
13. Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis.
Conaghan PG; Østergaard M; Troum O; Bowes MA; Guillard G; Wilkinson B; Xie Z; Andrews J; Stein A; Chapman D; Koenig A
Arthritis Res Ther; 2019 Oct; 21(1):214. PubMed ID: 31639034
[TBL] [Abstract][Full Text] [Related]
14. Six-month prospective trial in early and long-standing rheumatoid arthritis: evaluating disease activity in the wrist through sequential synovial histopathological analysis, RAMRIS magnetic resonance score and EULAR-OMERACT ultrasound score.
Just SA; Nielsen C; Werlinrud JC; Larsen PV; Klinkby CS; Schrøder HD; Humby F; Torfing T; Lindegaard H
RMD Open; 2019; 5(2):e000951. PubMed ID: 31413866
[TBL] [Abstract][Full Text] [Related]
15. Bone oedema predicts erosive progression on wrist MRI in early RA--a 2-yr observational MRI and NC scintigraphy study.
Palosaari K; Vuotila J; Takalo R; Jartti A; Niemelä RK; Karjalainen A; Haapea M; Soini I; Tervonen O; Hakala M
Rheumatology (Oxford); 2006 Dec; 45(12):1542-8. PubMed ID: 16670155
[TBL] [Abstract][Full Text] [Related]
16. Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission.
Møller-Bisgaard S; Georgiadis S; Hørslev-Petersen K; Ejbjerg B; Hetland ML; Ørnbjerg LM; Glinatsi D; Møller J; Boesen M; Stengaard-Pedersen K; Madsen OR; Jensen B; Villadsen JA; Hauge EM; Bennett P; Hendricks O; Asmussen K; Kowalski M; Lindegaard H; Bliddal H; Krogh NS; Ellingsen T; Nielsen AH; Balding L; Jurik AG; Thomsen HS; Østergaard M
Rheumatology (Oxford); 2021 Jan; 60(1):380-391. PubMed ID: 32929463
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of rheumatoid arthritis magnetic resonance imaging inflammation thresholds associated with lack of damage progression.
Baker JF; Østergaard M; Emery P; Baker DG; Conaghan PG
Clin Exp Rheumatol; 2017; 35(4):607-613. PubMed ID: 28134079
[TBL] [Abstract][Full Text] [Related]
18. Determining a magnetic resonance imaging inflammatory activity acceptable state without subsequent radiographic progression in rheumatoid arthritis: results from a followup MRI study of 254 patients in clinical remission or low disease activity.
Gandjbakhch F; Haavardsholm EA; Conaghan PG; Ejbjerg B; Foltz V; Brown AK; Døhn UM; Lassere M; Freeston JE; Olsen IC; Bøyesen P; Bird P; Fautrel B; Hetland ML; Emery P; Bourgeois P; Hørslev-Petersen K; Kvien TK; McQueen FM; Østergaard M
J Rheumatol; 2014 Feb; 41(2):398-406. PubMed ID: 24334647
[TBL] [Abstract][Full Text] [Related]
19. Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis.
Baker JF; Conaghan PG; Emery P; Baker DG; Østergaard M
Ann Rheum Dis; 2016 Jun; 75(6):1114-9. PubMed ID: 26091907
[TBL] [Abstract][Full Text] [Related]
20. The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy.
Conaghan PG; Peterfy C; Olech E; Kaine J; Ridley D; Dicarlo J; Friedman J; Devenport J; Troum O
Ann Rheum Dis; 2014 May; 73(5):810-6. PubMed ID: 24525910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
